We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-9.2%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$707M
AUM Growth
-$184M
Cap. Flow
-$68.9M
Cap. Flow %
-9.74%
Top 10 Hldgs %
88.63%
Holding
27
New
1
Increased
–
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$10.7M

Top Sells

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$48.3M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.22M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$5.77M
4
CDTX
Cidara Therapeutics
CDTX
+$4.49M
5
REPL icon
Replimune Group
REPL
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$195M 27.59%
22,957,340
-5,255,036
-19% -$48.3M
REPL icon
2
Replimune Group
REPL
$814M
$129M 18.25%
4,763,380
-132,694
-3% -$3.97M
IMGO
3
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$71.6M 10.12%
3,018,737
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$56.9M 8.04%
1,200,014
-115,938
-9% -$6.22M
KRON
5
DELISTED
Kronos Bio
KRON
$51.9M 7.34%
3,818,283
– –
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$35.8M 5.06%
3,164,835
-155,773
-5% -$1.85M
IMA
7
ImageneBio Inc
IMA
$63.1M
$28.2M 3.99%
187,427
– –
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$28.1M 3.97%
2,029,580
– –
IMUX icon
9
Immunic
IMUX
$182M
$17.1M 2.42%
178,816
– –
SANA icon
10
Sana Biotechnology
SANA
$885M
$13.1M 1.85%
843,750
– –
ARQT icon
11
Arcutis Biotherapeutics
ARQT
$3.42B
$12.9M 1.83%
623,836
– –
ICVX
12
DELISTED
Icosavax, Inc. Common Stock
ICVX
$9.76M 1.38%
426,395
– –
SPRB
13
Spruce Biosciences
SPRB
$119M
$9.64M 1.36%
28,814
– –
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$9.02M 1.28%
+711,479
New +$10.7M
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.85M 1.25%
1,971,241
-635,568
-24% -$3.02M
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.19M 1.16%
251,271
– –
OMEG
17
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.89M 0.69%
501,000
– –
EPIX
18
DELISTED
ESSA Pharma
EPIX
$4.66M 0.66%
328,196
– –
IVVD icon
19
Invivyd
IVVD
$180M
$4.59M 0.65%
632,855
– –
CMPI
20
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$3.83M 0.54%
1,335,050
– –
JNCE
21
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.3M 0.33%
275,513
– –
IMCR icon
22
Immunocore
IMCR
$1.78B
$1.76M 0.25%
51,535
– –
AVIR icon
23
Atea Pharmaceuticals
AVIR
$379M
– –
-164,577
Closed -$5.77M
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
– –
-100,262
Closed -$4.49M
KYNB
25
Kyntra Bio
KYNB
$28.5M
– –
-5,226
Closed -$1.15M
1
2

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2021 Portfolio in Review

As of Q4 2021, Omega Fund Management held 27 positions worth $707M, down 21% from $891M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Omega Fund Management withdrew a net $68.9M in Q4 2021, closing 5 positions and reducing 5 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $5.77M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Omega Fund Management opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $9.02M.

  • Omega Fund Management's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 711,479 shares worth $9.02M.
  • Omega Fund Management's biggest Q4 2021 reduction was Nuvation Bio, cutting an estimated $48.3M.
  • Omega Fund Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $5.77M.
  • Omega Fund Management's ten largest holdings make up 89% of its $707M portfolio in Q4 2021.
  • Omega Fund Management opened 1 new position and closed 5 in Q4 2021.
  • Omega Fund Management's portfolio value fell 21% quarter-over-quarter to $707M.

Based on Omega Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.